Clinical Research Progress of the Non-Peptide Oral Somatostatin Receptor Ligand Paltusotine / 罕见病研究
JOURNAL OF RARE DISEASES
;
(4): 414-419, 2023.
Artículo
en Inglés
| WPRIM
| ID: wpr-1004968
ABSTRACT
The research and development of somatostatin analogues is a hot area in endocrinology and metabolism. The first generation octreotide, lanreotide and the second generation pareotide have been approved to be effective for the treatment of neuroendocrine tumors such as acromegaly. However, paltusotine, a somatostatin receptor ligand, is a novel non-peptide small molecule drug which can be administered orally and inhibits excessive secretion of growth hormone and insulin-like growth factor 1. This review summarizes the research progress of the pharmacokinetics, pharmacodynamics, clinical efficacy, telerability, and safety of paltusotine.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Inglés
Revista:
JOURNAL OF RARE DISEASES
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS